Compound 194 (left) was developed by researchers to uncouple the interaction between CRMP2 and the enzyme Ubc9, which indirectly regulates the sodium ion channel NaV1.7. A new study showed that the resulting reduction in sodium currents reduced pain.
(Image: Samantha Perez-Miller, Aude Chefdeville and Rajesh Khanna)
Researchers at the University of Arizona Health Sciences are closer to developing a safe and effective non-opioid pain reliever after a study showed that a new compound they created reduces the sensation of pain by regulating a biological channel linked to pain.
Most people experience pain at some point in their lives, and the National Institutes of Health estimates 100 million people in the U.S. suffer from chronic pain. Approximately 21-29% of patients prescribed opioids for chronic pain misuse them and 8-12% of people using an opioid for chronic pain develop an opioid use disorder, according to the National Institute on Drug Abuse. In 2019, nearly 50,000 people in the U.S. died from opioid-involved overdoses.
“Drug discovery for chronic pain is at the forefront of this research, and it’s being amplified by the intersection of the COVID-19 pandemic and the opioid epidemic,” said Rajesh Khanna, PhD, associate director of the UArizona Health Sciences Comprehensive Pain and Addiction Center, professor of pharmacology in the UArizona College of Medicine – Tucson and a member of the BIO5 Institute. “Drug discovery is a very arduous process. Our lab looked at a fundamental mechanism of pain, came up with a way to differentiate it from those before us and found a compound that has potential as a new non-opioid treatment for pain.”
The paper, “Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents,” was published today in Science Translational Medicine.
The biological mechanism at the heart of the research is NaV1.7, a sodium ion channel that previously was linked to the sensation of pain through genetic studies of people with rare pain disorders.
Nerve cells, or neurons, use electrical currents to send signals to the brain and throughout the body, and sodium ion channels are vital to a cell’s ability to generate those electrical currents. When a neuron is stimulated, the NaV1.7 channel opens and allows positively charged sodium ions to cross the cell membrane and enter the previously negatively charged cell. The change in charge across the cell membrane generates an electrical current, which increases the excitability of the neuron and sets in motion a cascade of events that leads to pain.
Because NaV1.7 is a human-validated target for pain, multiple attempts have tried to stop pain by using sodium ion channel inhibitors to block NaV1.7. None have been successful. Dr. Khanna and his team took a different approach – rather than block NaV1.7, they wanted to indirectly regulate it.
Using a compound they designed and dubbed 194, the team successfully regulated NaV1.7 activation in the laboratory using nerve cells from four different species, including humans. In animal models, 194 was effective in reversing pain in six different pain models in both sexes.
Researchers also found that 194 may promote pain relief by activating the body’s endogenous, or naturally occurring, opioid system. Once produced, endogenous opioids activate receptors that produce physiological changes such as pain relief. And 194 did so without causing motor performance issues, depressive behaviors or addiction.
Finally, Dr. Khanna and the team observed a synergistic effect when 194 was combined with morphine and gabapentin. This is a promising sign that 194 could be used in a dose-reduction strategy for painkillers that have negative side effects, including opioids, while maintaining high levels of pain relief.
The science behind 194
Dr. Khanna’s prior research identified a protein, collapsin response mediator protein 2 (CRMP2), and an enzyme, Ubc9, that both play a role in NaV1.7 activation. CRMP2 is a protein that binds to NaV1.7 and transports it to the cell membrane, where sodium ions are then transferred into the cell. Ubc9 is an enzyme that tags CRMP2 with another protein – a small ubiquitin-like modifier protein – to specifically direct control of NaV1.7.
Building on this knowledge, Dr. Khanna and the team set out to determine if they could directly regulate the activity of NaV1.7 by blocking Ubc9 from interacting with CRMP2. Team members including May Khanna, PhD, associate professor of pharmacology and BIO5 Institute member, Vijay Gokhale, PhD, associate research professor in the BIO5 Institute, and Samantha Perez-Miller, PhD, researcher and scientist in the Department of Pharmacology, examined 50,000 existing small molecules to identify the ones with a structure similar to Ubc9.
They selected less than 50 of the closest matches, which were then tested in Dr. Khanna’s laboratory to see if their presence would suppress the influx of sodium through NaV1.7. The findings were promising, so the team set their sights on developing a unique, more effective compound.
The result was 194, which UArizona patented and licensed to startup Regulonix LLC through Tech Launch Arizona, the UArizona office that commercializes inventions stemming from university research. Drs. Khanna and Gokhale founded Regulonix LLC in 2016 to address the growing opioid epidemic by developing new, non-addictive ways to treat pain and commercializing those innovations.
While 194 shows great promise for pain relief, Dr. Khanna and the team have been working with the National Institutes of Health’s National Center for Advancing Translational Sciences to optimize the compound. In this case, an NCATS team is primarily focusing on improving 194’s half-life – the time it takes for a drug to reduce by half in your body – and its drug-like properties.
It is an important step in optimizing the compound’s potential as a pain-relieving drug and advancing to the next stage, where researchers will file for Food and Drug Administration approval to begin clinical trials.
More from: University of Arizona
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Non-opioid pain reliever
- Opioids over-prescribed after total joint arthroplasty, finds study
Opioids are over-prescribed after total joint arthroplasty, Finds a new study appearing in Journal of Orthopaedics.As the current opioid epidemic in the United States continues to escalate, ...
- Treating Chronic Pain with Devices and Drugs: Options Available for the Afflicted
The world is in pain! Chronic pain “...exerts an enormous personal and economic burden, affecting more than 30% of people worldwide.”, says an article in The Lancet. Persisting for up to three months ...
- Non-Opioid Pain Treatment Market Set to Expand by 2022-2029 Focusing on Key Players – Pfizer, Eli Lilly, Teva, Novartis, US WorldMeds
The Global Non-Opioid Pain Treatment Market is expected to USD 4.99 billion by 2029 growing at a CAGR of 3.15% in the forecast period of 2022 to 2029. The wide ranging Non-Opioid Pain Treatment Market ...
- ‘Deaths of despair’: Research on opioid crisis origins and the link between minimum wages and suicide reduction
Recent research details the rise of OxyContin in the U.S. and how three pieces of paper spared some parts of the country from the worst of the opioid crisis.
- West Valley City paramedics now carrying non-opioid medications to combat opioid crisis
West Valley City Fire and EMS crews are now carrying two non-opioid pain medications to give to patients they treat in an effort to combat the opioid epidemic. "The first is IV acetaminophen, which ...
Go deeper with Google Headlines on:
Non-opioid pain reliever
Go deeper with Bing News on:
- AIMRC Seminar on Deciphering Corticospinal Circuits in Controlling Touch and Tactile Neuropathic Pain Sensitivity
During his postdoc career, he optimized an elegant, multi-step viral-based intersectional targeting tool, which he used to dissect the role of corticospinal neurons in controlling distinct spinal ...
- Chronic Pain Treatment Market
The global chronic pain treatment market valued $80,766. 6 million in 2020, from where it is set to reach $162,175. 2 million by 2030, at a 7. 2% CAGR between 2020 and 2030. This will be majorly ...
- Buckley teen enjoying 'life 2.0' after years of chronic pain
MALS is a cause of chronic abdominal pain affecting children and adults. MALS is a condition in which the median arcuate ligament presses too tightly on the celiac artery and the ...
- Medtronic : FDA Okays Spinal Cord Stimulation Therapy For Treating Chronic Pain Resulting From DPN
Medtronic plc (MDT) said Monday that the U.S. Food and Drug Administration approved its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic pain ...
- FDA approves Medtronic’s spinal cord stimulation for chronic pain from diabetic neuropathy
Medtronic (NYSE:MDT) announced today the FDA approved its Intellis and Vanta neurostimulator for treating chronic pain.